ecrin-mdr-crcClinical2017IPD Sharing (as of September 2022): NoAdvanced MalignanciesEndometrial cancerNon-small cell lung cancer (NSCLC)MelanomaMesotheliomaNeoplasmsEsophageal cancerOvarian cancerEndometrial CancerOvarian CancerAdvanced MalignanciesMelanomaEsophageal CancerMesotheliomaNon-small Cell Lung Cancer (nsclc)NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2251135United States10Advanced or metastatic cervical cancerMerkel cell carcinomaIpilimumabHepatocellular carcinoma (HCC)SCCHNTriple-negative breast cancerSquamous cell carcinoma of the head and neckSmall cell lung cancer (SLCL)NivolumabRenal cell carcinoma (RCC)MSI-H CRCUrothelial carcinomaTNBCMicrosatellite instability-high colorectal cancerGastric cancer (including stomach and gastroesophageal junction [GEJ])OX40 ligand (OX40)ECRIN MDRCompletedfalseA Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesThe purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.2017-10-152251135NCT03241173